CA2387621A1 - Extended release formulations of erythromycin derivatives - Google Patents
Extended release formulations of erythromycin derivatives Download PDFInfo
- Publication number
- CA2387621A1 CA2387621A1 CA002387621A CA2387621A CA2387621A1 CA 2387621 A1 CA2387621 A1 CA 2387621A1 CA 002387621 A CA002387621 A CA 002387621A CA 2387621 A CA2387621 A CA 2387621A CA 2387621 A1 CA2387621 A1 CA 2387621A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- extended release
- erythromycin derivative
- polymer
- release pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/416,916 | 1999-10-13 | ||
US09/416,916 US6551616B1 (en) | 1997-04-11 | 1999-10-13 | Extended release formulations of erythromycin derivatives |
PCT/US2000/028407 WO2001026663A1 (en) | 1999-10-13 | 2000-10-13 | Extended release formulations of erythromycin derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2387621A1 true CA2387621A1 (en) | 2001-04-19 |
Family
ID=23651825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002387621A Abandoned CA2387621A1 (en) | 1999-10-13 | 2000-10-13 | Extended release formulations of erythromycin derivatives |
Country Status (14)
Country | Link |
---|---|
US (3) | US6551616B1 (pt) |
EP (1) | EP1223949A1 (pt) |
KR (1) | KR20020068522A (pt) |
AR (1) | AR026045A1 (pt) |
AU (1) | AU1203601A (pt) |
BG (1) | BG106683A (pt) |
BR (1) | BR0010485A (pt) |
CA (1) | CA2387621A1 (pt) |
HU (1) | HUP0203540A3 (pt) |
IL (1) | IL149033A0 (pt) |
NO (1) | NO20021747D0 (pt) |
PL (1) | PL354783A1 (pt) |
SK (1) | SK4862002A3 (pt) |
WO (1) | WO2001026663A1 (pt) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6551616B1 (en) * | 1997-04-11 | 2003-04-22 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US6565882B2 (en) * | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
AU2578701A (en) * | 2000-02-29 | 2001-09-12 | Teva Pharma | Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same |
US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
US6541014B2 (en) * | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
US6878751B1 (en) * | 2000-10-19 | 2005-04-12 | Imperial College Of Science Technology And Medicine | Administration of resveratrol to treat inflammatory respiratory disorders |
US20020197314A1 (en) * | 2001-02-23 | 2002-12-26 | Rudnic Edward M. | Anti-fungal composition |
US6642276B2 (en) * | 2001-10-01 | 2003-11-04 | M/S Ind-Swift Limited | Controlled release macrolide pharmaceutical formulations |
EP2422775A3 (en) * | 2002-09-20 | 2012-04-18 | Alpharma, Inc. | Sequestering subunit and related compositions and methods |
US20040191302A1 (en) | 2003-03-28 | 2004-09-30 | Davidson Robert S. | Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films |
US8999372B2 (en) * | 2002-11-14 | 2015-04-07 | Cure Pharmaceutical Corporation | Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use |
US9561182B2 (en) * | 2003-08-22 | 2017-02-07 | Cure Pharmaceutical Corporation | Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals |
US20040131662A1 (en) | 2003-11-12 | 2004-07-08 | Davidson Robert S. | Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films |
AU2004258953B2 (en) | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
US8313776B2 (en) | 2003-07-21 | 2012-11-20 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
EP1648418A4 (en) | 2003-07-21 | 2011-11-16 | Middlebrook Pharmaceuticals Inc | ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION |
US20050025825A1 (en) * | 2003-07-31 | 2005-02-03 | Xanodyne Pharmacal, Inc. | Tranexamic acid formulations with reduced adverse effects |
US20090214644A1 (en) * | 2003-07-31 | 2009-08-27 | Xanodyne Pharmaceuticals, Inc. | Tranexamic acid formulations with reduced adverse effects |
EP1653925A1 (en) * | 2003-08-11 | 2006-05-10 | Advancis Pharmaceutical Corporation | Robust pellet |
AU2004264356B2 (en) | 2003-08-12 | 2011-01-27 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
JP5686494B2 (ja) | 2003-08-29 | 2015-03-18 | シオノギ インコーポレイテッド | 抗生物質製剤、その使用法及び作成方法 |
WO2005027877A1 (en) | 2003-09-15 | 2005-03-31 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
WO2005053653A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride |
EP1691787B1 (en) * | 2003-12-04 | 2008-07-02 | Pfizer Products Inc. | Method for making pharmaceutical multiparticulates |
BRPI0416534A (pt) * | 2003-12-04 | 2007-01-09 | Pfizer Prod Inc | composições multiparticuladas com estabilidade melhorada |
US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
WO2005053639A2 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Controlled release multiparticulates formed with dissolution enhancers |
CA2549225A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride |
RU2006119453A (ru) * | 2003-12-04 | 2007-12-20 | Пфайзер Продактс Инк. (Us) | Получение посредством основанных на применении жидкостей способов лекарственные формы азитромицина с большим количеством частиц |
WO2005053652A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
EP1701705A4 (en) * | 2003-12-24 | 2007-08-08 | Advancis Pharmaceutical Corp | IMPROVED ABSORPTION OF MODIFIED RELEASE DOSAGE FORMS |
US7947739B2 (en) | 2004-03-04 | 2011-05-24 | Ferring B.V. | Tranexamic acid formulations |
US20050244495A1 (en) * | 2004-03-04 | 2005-11-03 | Xanodyne Pharmaceuticals, Inc. | Tranexamic acid formulations |
US8022106B2 (en) * | 2004-03-04 | 2011-09-20 | Ferring B.V. | Tranexamic acid formulations |
US20050245614A1 (en) * | 2004-03-04 | 2005-11-03 | Xanodyne Pharmaceuticals, Inc. | Tranexamic acid formulations |
US20090215898A1 (en) * | 2004-03-04 | 2009-08-27 | Xanodyne Pharmaceuticals, Inc. | Tranexamic acid formulations |
US20050260263A1 (en) * | 2004-05-18 | 2005-11-24 | Panion & Bf Biotech Inc. | Sustained release formulation for sparingly soluble main drugs |
JP2008505124A (ja) | 2004-07-02 | 2008-02-21 | アドバンシス ファーマスーティカル コーポレイション | パルス送達用錠剤 |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
US8778924B2 (en) * | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
JP2009539866A (ja) * | 2006-06-05 | 2009-11-19 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 置換エリスロマイシンアナログの調製および有用性 |
CA2655835C (en) * | 2006-06-19 | 2015-07-21 | Alpharma, Inc. | Abuse-resistant pharmaceutical compositions of opioid agonists |
EP2073797A2 (en) * | 2006-10-11 | 2009-07-01 | Alpharma, Inc. | Pharmaceutical compositions |
EP2224808A4 (en) * | 2007-12-17 | 2013-11-27 | Alpharma Pharmaceuticals Llc | PHARMACEUTICAL COMPOSITION |
US8623418B2 (en) * | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
AU2008338442A1 (en) * | 2007-12-17 | 2009-06-25 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
US20100151014A1 (en) * | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
GB0903262D0 (en) * | 2009-02-26 | 2009-04-08 | Johnson Matthey Plc | Filter |
US20100280117A1 (en) * | 2009-04-30 | 2010-11-04 | Xanodyne Pharmaceuticals, Inc. | Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders |
WO2011068721A1 (en) * | 2009-12-03 | 2011-06-09 | Opko Health, Inc. | Hypersulfated disaccharide formulations |
TW201815394A (zh) | 2016-08-16 | 2018-05-01 | 美商歐科製藥有限公司 | 具有改良口服生物可利用性之純七硫酸化雙醣 |
US20190247331A1 (en) | 2018-02-15 | 2019-08-15 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
US10213394B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
US10213393B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság | Composition and method for treating neurological disease |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3065143A (en) | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
US3870790A (en) | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
US4226849A (en) | 1979-06-14 | 1980-10-07 | Forest Laboratories Inc. | Sustained release therapeutic compositions |
US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
FI69254C (fi) | 1984-02-01 | 1986-01-10 | Lujari Instmsto Oy | Anordning foer avskiljande av fasta aemnen fraon avfallsvatten |
ATE66143T1 (de) | 1985-01-11 | 1991-08-15 | Abbott Lab | Feste zubereitung mit langsamer freisetzung. |
FR2585948B1 (fr) | 1985-08-06 | 1988-12-16 | Pf Medicament | Procede de fabrication de comprimes d'indometacine |
DE3613799C1 (de) * | 1986-04-24 | 1987-09-03 | Nattermann A & Cie | Verwendung von Glycofurol zum Verfluessigen von Arzneimittelzubereitungen fuer das Abfuellen in Weichgelatinekapseln |
US4808411A (en) | 1987-06-05 | 1989-02-28 | Abbott Laboratories | Antibiotic-polymer compositions |
JPH01308223A (ja) | 1988-02-22 | 1989-12-12 | Taisho Pharmaceut Co Ltd | 均質な微細皮膜製剤の製造方法 |
US4925675A (en) | 1988-08-19 | 1990-05-15 | Himedics, Inc. | Erythromycin microencapsulated granules |
US4925765A (en) * | 1988-12-23 | 1990-05-15 | E. I. Du Pont De Nemours And Company | Negative solid block toner |
US5017383A (en) | 1989-08-22 | 1991-05-21 | Taisho Pharmaceutical Co., Ltd. | Method of producing fine coated pharmaceutical preparation |
JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
TW271400B (pt) * | 1992-07-30 | 1996-03-01 | Pfizer | |
US5393765A (en) | 1993-12-13 | 1995-02-28 | Hoffmann-La Roche Inc. | Pharmaceutical compositions with constant erosion volume for zero order controlled release |
JP2977907B2 (ja) | 1994-05-06 | 1999-11-15 | ファイザー・インコーポレーテッド | アジスロマイシンの放出調節された剤形 |
US5919489A (en) | 1995-11-01 | 1999-07-06 | Abbott Laboratories | Process for aqueous granulation of clarithromycin |
US5705190A (en) * | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
DE19706979A1 (de) | 1997-02-21 | 1998-08-27 | Lindopharm Gmbh | Kombinationspräparat für oral applizierbare Erythromycine |
DE19706978A1 (de) | 1997-02-21 | 1998-08-27 | Ulrich Dr Posanski | Kombinationspräparat für oral applizierbare Antibiotika |
US6010718A (en) | 1997-04-11 | 2000-01-04 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
US6551616B1 (en) * | 1997-04-11 | 2003-04-22 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
EP0943341A1 (en) | 1998-02-18 | 1999-09-22 | Oscar Gold | Procedure to prepare granulated compositions that contain erythromycin macrolides and procedure to prepare pharmaceutical compositions that contain said macrolides |
-
1999
- 1999-10-13 US US09/416,916 patent/US6551616B1/en not_active Expired - Lifetime
-
2000
- 2000-10-13 AU AU12036/01A patent/AU1203601A/en not_active Abandoned
- 2000-10-13 AR ARP000105406A patent/AR026045A1/es unknown
- 2000-10-13 PL PL00354783A patent/PL354783A1/xx not_active Application Discontinuation
- 2000-10-13 EP EP00973534A patent/EP1223949A1/en not_active Withdrawn
- 2000-10-13 SK SK486-2002A patent/SK4862002A3/sk unknown
- 2000-10-13 HU HU0203540A patent/HUP0203540A3/hu unknown
- 2000-10-13 KR KR1020027004725A patent/KR20020068522A/ko not_active Application Discontinuation
- 2000-10-13 BR BR0010485-0A patent/BR0010485A/pt not_active Application Discontinuation
- 2000-10-13 WO PCT/US2000/028407 patent/WO2001026663A1/en not_active Application Discontinuation
- 2000-10-13 IL IL14903300A patent/IL149033A0/xx unknown
- 2000-10-13 CA CA002387621A patent/CA2387621A1/en not_active Abandoned
-
2002
- 2002-04-12 NO NO20021747A patent/NO20021747D0/no unknown
- 2002-05-09 BG BG106683A patent/BG106683A/bg unknown
- 2002-11-22 US US10/302,166 patent/US6872407B2/en not_active Expired - Lifetime
-
2005
- 2005-03-28 US US11/091,637 patent/US20060039969A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BG106683A (bg) | 2002-12-29 |
HUP0203540A3 (en) | 2003-03-28 |
US6872407B2 (en) | 2005-03-29 |
AR026045A1 (es) | 2002-12-26 |
WO2001026663A1 (en) | 2001-04-19 |
NO20021747D0 (no) | 2002-04-12 |
PL354783A1 (en) | 2004-02-23 |
US20030133981A1 (en) | 2003-07-17 |
HUP0203540A2 (hu) | 2003-02-28 |
AU1203601A (en) | 2001-04-23 |
EP1223949A1 (en) | 2002-07-24 |
US20060039969A1 (en) | 2006-02-23 |
US6551616B1 (en) | 2003-04-22 |
IL149033A0 (en) | 2002-11-10 |
SK4862002A3 (en) | 2002-10-08 |
KR20020068522A (ko) | 2002-08-27 |
BR0010485A (pt) | 2002-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2285266C (en) | Extended release formulations of erythromycin derivatives | |
US6551616B1 (en) | Extended release formulations of erythromycin derivatives | |
JPH061716A (ja) | 活性成分の長期放出性を有する投薬形 | |
PL197448B1 (pl) | Preparat farmaceutyczny o zmodyfikowanym uwalnianiu zawierający amoksycylinę i klawulanian potasowy oraz zastosowanie amoksycyliny i klawulanianu potasowego | |
US20050064033A1 (en) | Extended release formulations of erythromycin derivatives | |
US20040024018A1 (en) | Sustained-release preparations of quinolone antibiotics and method for preparation thereof | |
WO2004078111A2 (en) | Extended release minocycline compositions and processes for their preparation | |
CA2358395C (en) | Extended release formulations of erythromycin derivatives | |
CA2325541C (en) | Extended release formulations of erythromycin derivatives | |
AU2007201031B2 (en) | Extended release formulations of erythromycin derivatives | |
AU773863B2 (en) | Extended release formulations of erythromycin derivatives | |
AU2003270948B2 (en) | Extended Release Formulations of Erythromycin Derivatives | |
CA2465698A1 (en) | Extended release formulations of erythromycin derivatives | |
AU2006201001A1 (en) | Extended release formulations of erythromycin derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |